Pre-operative Plasma Concentrations of Choline and Its Metabolites in People With Prostate Cancer Compared to Those With Benign Hyperplasia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Primary Prostate Urothelial Cancer
- Sponsor
- Universität des Saarlandes
- Enrollment
- 350
- Locations
- 1
- Primary Endpoint
- Plasma choline concentrations
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim of this study was to investigate plasma concentrations of one-carbon metabolites and phospholipid classes in participants with primary prostate cancer and those with benign hyperplasia. Moreover, the metabolites were studied in relation to tumor grade and age.
Detailed Description
This observational study recruited participants with primary prostate cancer (cases) and those with benign hyperplasia (controls) before the surgery. Data on the outcomes of the surgery including the results of the biopsy investigation were collected. Blood samples were collected before the surgery in context of routine blood investigations. Blood plasma samples collected on ethylenediaminetetraacetic acid (EDTA) were used to measure concentrations of free choline, betaine, dimethylglycine, folate forms, S-adenosylhomocysteine, S-adenosylmethionine, homocysteine, cystathionine, and methylmalonic acid (MMA). Data on serum concentrations of prostate specific antigen (PSA) and the tumor grade and classification (Gleason Score system) were collected. The associations between the plasma concentrations of the metabolites and PSA or the Gleason score were studied. The concentrations of the metabolic markers were compared between the cases and the controls according to the age of the participants.
Investigators
Rima Obeid
Prof. Dr.
Universität des Saarlandes
Eligibility Criteria
Inclusion Criteria
- •Men participants
- •age \> 50 years
- •recently diagnosed with primary prostate cancer or benign hyperplasia
Exclusion Criteria
- •vitamin B supplementation (folic acid\> 400 µg / day; B12\> 10 µg / day; B6\> 10 mg / day)
- •renal failure
- •advanced liver disease
- •chronic alcohol consumption
- •metastases
- •methotrexate therapy.
Outcomes
Primary Outcomes
Plasma choline concentrations
Time Frame: through study completion, on average 1 year
Concentrations measured in plasma with liquid chromatography tandem mass spectrometry
Whole blood choline concentrations
Time Frame: through study completion, on average 1 year
Concentrations measured in plasma with liquid chromatography tandem mass spectrometry
Secondary Outcomes
- Plasma homocysteine concentrations(through study completion, on average 1 year)
- Plasma phospholipids(through study completion, on average 1 year)
- Plasma betaine concentrations(through study completion, on average 1 year)
- Plasma methylmalonic acid concentrations(through study completion, on average 1 year)
- Plasma and whole blood folate forms(through study completion, on average 1 year)
- Plasma S-adenosylmethionine concentrations(through study completion, on average 1 year)